biotech.today

Details

  • ●Modalities: active immunotherapy (vaccines), small molecules, antibodies, diagnostics
  • ●Therapeutic areas: neuroscience
  • ●Key targets: amyloid-beta, phospho-tau, alpha-synuclein, TDP-43
  • ●Indications: Alzheimer's disease, Parkinson's disease, Down syndrome, progressive supranuclear palsy
  • ●Funding: $500M+ (lifetime, public)

Partners & investors

  • Public (Nasdaq: ACIU)· Investor
  • Janssen (J&J)· Investor
  • Roche/Genentech· Investor
  • Life Sciences Partners· Investor

Key considerations

  • ●AI tools in use: SupraAntigen platform (conformational epitope design), Morphomer platform (small molecule protein misfolding)
  • ●AI/computational approaches to conformational epitope identification
  • ●Roche/Genentech partnership (diagnostics)
  • ●Janssen (J&J) partnership on anti-tau vaccine

Pipeline

  • Phase 12
  • Phase 22
Get live updates on AC Immune’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Andrea Pfeifer

Co-Founder & CEO

neurosciencevaccine developmentbiotech entrepreneurship
Visit website →LinkedIn →